Clinical Cancer Research
Oct 01, 2026
Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in Patients with Advanced Hepatocellular Carcinoma
Xuqi Sun, Wanwan Gao, Chunhui Shou, Junyi Yan, Qihan Fu, Yi Zheng, Lulu Liu, You Zhai, Zhou Tong, Hangyu Zhang, Bin Li, Meihua Lin, Xudong Zhu, Yumeng Wang, Daijing Yuan, Xuanwen Bao, Xiaomeng Dai, Yi Luo, Hua Jiang, Huamao Wang, Peng Zhao, Qingwei Zhao, Weijia Fang, Zonghai Li, Tingbo Liang
Blood
Sep 03, 2026
A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study
Song Jin, Zhaohui Liao, Shuang Yan, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Fang Tang, Ziling Zhu, Depei Wu, Nishanthan Rajakumaraswamy, Yi Luo, Daijing Yuan, Hua Jiang, Zonghai Li, Chengcheng Fu
Blood Advances
Oct 29, 2025
Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma
Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Daijing Yuan, Huamao Wang, Zonghai Li
The Lancet Haematology
Oct 08, 2025
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
Lina Jin, Sinan Gu, Qianqi Ruan, Jing Lu, Wanting Qiang, Haiyan He, Xiaoqiang Fan, Jin Liu, Pei Guo, Xingxing Meng, Nishanthan Rajakumaraswamy, Deng Chen, Zonghai Li, Juan Du
Experimental Hematology & Oncology
Sep 30, 2025
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma
Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, Wei Yang, Siguo Hao, Songfu Jiang, Hongmei Jing, Jing Liu, Xin Du, Rong Fu, Heng Mei, Zunmin Zhu, Yanli Yang, Hong Liu, Xingxing Meng, Nishanthan Rajakumaraswamy, Daijing Yuan, Huamao Wang & Zonghai Li
The Lancet
May 31, 2025
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
Changsong Qi, Chang Liu, Zhi Peng, Yanqiao Zhang, Jia Wei, Wensheng Qiu, Xiaotian Zhang, Hongming Pan, Zuoxing Niu, Meng Qiu, Yanru Qin, Weijia Fang, Feng Ye, Ning Li, Tianshu Liu, Anwen Liu, Xizhi Zhang, Changlu Hu, Jun Zhang, Jiuwei Cui, Xiaoyan Lin, Shubin Wang, Jian Zhang, Tongyu Lin, Xiujuan Qu, Xianglin Yuan, Jifang Gong, Jian Li, Wanwan Gao, Lun Gai, Yumeng Wang, Daijing Yuan, Zonghai Li, Lin Shen
Molecular Diagnosis & Therapy
Jun 18, 2024
Zevorcabtagene Autoleucel: First Approval
Sohita Dhillon
Nature Medicine
Jun 03, 2024
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Changsong Qi, Chang Liu, Jifang Gong, Dan Liu, Xicheng Wang, Panpan Zhang, Yanru Qin, Sai Ge, Miao Zhang, Zhi Peng, Jun Zhou, Zhihao Lu, Ming Lu, Yanshuo Cao, Jiajia Yuan, Yakun Wang, Zhenghang Wang, Ran Xue, Xiaohui Peng, Yumeng Wang, Daijing Yuan, Jian Li, Xiaotian Zhang, Lin Shen
Journal of Clinical Oncology
May 24, 2024
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials
Changsong Qi, Panpan Zhang, Chang Liu, Jun Zhang, Jun Zhou, Jiajia Yuan, Dan Liu, Miao Zhang, Jifang Gong, Xicheng Wang, Jian Li, Xiaotian Zhang, Ning Li, Xiaohui Peng, Zhen Liu, Daijing Yuan, Raffaele Baffa, Yumeng Wang, Lin Shen
Chinese Journal of Cancer Research
Feb 29, 2024
Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study
Changsong Qi, Xiaoyi Chong, Ting Zhou, Mingyang Ma, Jifang Gong, Miao Zhang, Jian Li, Jun Xiao, Xiaohui Peng, Zhen Liu, Zonghai Li, Lin Shen, Xiaotian Zhang